U.S. MarketsSeptember 22 at 08:01 AM

Ionis (IONS) announces positive tope line results from Phase 3 study of Ulefnersen

StockNow breaking-news AI analysis

On September 22, 2026, Ionis Pharmaceuticals announced positive topline results from its Phase 3 study evaluating ulefnersen.

1 stocks

IONSIonis Pharmaceuticals, Inc. Common Stock$44.62Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

Iranian Parliament Speaker Ghalibaf says US President Trump cannot impose his power on Iran, adding that Iran will neither shut down nor surrender

IRGC says if Iran’s national interests require negotiations alongside war, then it must negotiate; says it will respond to any enemy strike with multiple strikes across different arenas and in various ways, Al Jazeera reports

Senior Iranian Official says that Tehran welcomes revival of diplomacy if the US takes tangible steps